

This variation is to include a 'new build' operation within the existing permit. The new build manufacturing suites remain close to its currently permitted site within the multi-operator installation run by CalaChem.

The new manufacturing suites will produce batch sizes of up to 4kg with a capacity of up to 40 batches per year in each Antibody Drug Conjugate (ADC). Although this is classed as a large-scale production, less than 1 tonne of product will be produced annually.

Liquid effluent from the new facility will be treated by CalaChem Effluent Treatment Plant (ETP), other solid and liquid waste will be handled by a responsible waste management company under contract.

The energy use of the site is small. The new build has been designed to incorporate energy efficiency operating systems throughout.

Waste streams to air, aqueous effluent and solid/liquid wastes have been assessed to determine their environmental impact, overall there is minimal environmental impact from the operations activities.